Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1975 Jan;122(1):42–49.

Complications of systemic oral contraceptive therapy: Neoplasm--breast, uterus, cervix and vagina.

M A Sperling
PMCID: PMC1130263  PMID: 1089006

Full text

PDF
42

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams J. B., Wong M. S. Desmolase activity of normal and malignant human breast tissue. J Endocrinol. 1969 May;44(1):69–77. doi: 10.1677/joe.0.0440069. [DOI] [PubMed] [Google Scholar]
  2. Aldrich J. O., Henderson B. E., Townsend D. E. Diagnostic procedures for the stilbestrol-adenosis-carcinoma syndrome. N Engl J Med. 1972 Nov 2;287(18):934–934. doi: 10.1056/nejm197211022871820. [DOI] [PubMed] [Google Scholar]
  3. Argüelles A. E., Poggi U. L., Saborida C., Hoffman C., Chekherdemian M., Blanchard O. Endocrine profiles and breast cancer. Lancet. 1973 Jan 27;1(7796):165–168. doi: 10.1016/s0140-6736(73)90002-0. [DOI] [PubMed] [Google Scholar]
  4. Arthes F. G., Sartwell P. E., Lewison E. F. The pill, estrogens, and the breast. Epidemiologic aspects. Cancer. 1971 Dec;28(6):1391–1394. doi: 10.1002/1097-0142(197112)28:6<1391::aid-cncr2820280609>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  5. Bailar J. C., 3rd Thromboembolism and oestrogen therapy. Lancet. 1967 Sep 9;2(7515):560–560. doi: 10.1016/s0140-6736(67)90529-6. [DOI] [PubMed] [Google Scholar]
  6. Bank S., Marks I. N. Case reports. Hyperlipaemic pancreatitis and the pill. Postgrad Med J. 1970 Sep;46(539):576–578. doi: 10.1136/pgmj.46.539.576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Barton G. M., Freeman P. R., Lawson J. P. Oral contraceptives and serum lipids. J Obstet Gynaecol Br Commonw. 1970 Jun;77(6):551–554. doi: 10.1111/j.1471-0528.1970.tb03566.x. [DOI] [PubMed] [Google Scholar]
  8. Baum J. K., Bookstein J. J., Holtz F., Klein E. W. Possible association between benign hepatomas and oral contraceptives. Lancet. 1973 Oct 27;2(7835):926–929. doi: 10.1016/s0140-6736(73)92594-4. [DOI] [PubMed] [Google Scholar]
  9. Beck P. Comparison of the metabolic effects of chlormadinone acetate and conventional contraceptive steroids in man. J Clin Endocrinol Metab. 1970 Jun;30(6):785–791. doi: 10.1210/jcem-30-6-785. [DOI] [PubMed] [Google Scholar]
  10. Beck P. Contraceptive steroids: modifications of carbohydrate and lipid metabolism. Metabolism. 1973 Jun;22(6):841–855. doi: 10.1016/0026-0495(73)90056-5. [DOI] [PubMed] [Google Scholar]
  11. Beck P. Contraceptive steroids: modifications of carbohydrate and lipid metabolism. Metabolism. 1973 Jun;22(6):841–855. doi: 10.1016/0026-0495(73)90056-5. [DOI] [PubMed] [Google Scholar]
  12. Beck P., Wells S. A. Comparison of the mechanisms underlying carbohydrate intolerance in subclinical diabetic women during pregnancy and during post-partum oral contraceptive steroid treatment. J Clin Endocrinol Metab. 1969 Jun;29(6):807–818. doi: 10.1210/jcem-29-6-807. [DOI] [PubMed] [Google Scholar]
  13. Beckerhoff R., Luetscher J. A., Wilkinson, Gonzales C., Nokes G. W. Plasma renin concentration, activity and substrate in hypertension caused by oral contraceptives. J Clin Endocrinol Metab. 1972 Jun;34(6):1067–1073. doi: 10.1210/jcem-34-6-1067. [DOI] [PubMed] [Google Scholar]
  14. Beckerhoff R., Vetter W., Armbruster H., Luetscher J. A., Siegenthaler W. Plasma-aldosterone during oral-contraceptive therapy. Lancet. 1973 Jun 2;1(7814):1218–1219. doi: 10.1016/s0140-6736(73)90530-8. [DOI] [PubMed] [Google Scholar]
  15. Bernstein G. S., Seward P. Daily chlormadinone acetate as an oral contraceptive. Contraception. 1972 May;5(5):369–388. doi: 10.1016/0010-7824(72)90029-7. [DOI] [PubMed] [Google Scholar]
  16. Bianchine J. R., Bonnlander B., Macaraeg P. V., Jr, Hersey R., Bianchine J. W., McIntyre P. A. Serum vitamin B 12 binding capacity and oral contraceptive hormones. J Clin Endocrinol Metab. 1969 Nov;29(11):1425–1428. doi: 10.1210/jcem-29-11-1425. [DOI] [PubMed] [Google Scholar]
  17. Bickerstaff E. R., Holmes J. M. Cerebral arterial insufficiency and oral contraceptives. Br Med J. 1967 Mar 25;1(5542):726–729. doi: 10.1136/bmj.1.5542.726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Bierman E. L., Porte D., Jr Carbohydrate intolerance and lipemia. Ann Intern Med. 1968 Apr;68(4):926–933. doi: 10.7326/0003-4819-68-4-926. [DOI] [PubMed] [Google Scholar]
  19. Bingel A. S., Benoit P. S. Oral contraceptives: therapeutics versus adverse reactions, with an outlook for the future I. J Pharm Sci. 1973 Feb;62(2):179–200. doi: 10.1002/jps.2600620202. [DOI] [PubMed] [Google Scholar]
  20. Bingel A. S., Benoit P. S. Oral contraceptives: therapeutics versus adverse reactions, with an outlook for the future. II. J Pharm Sci. 1973 Mar;62(3):349–362. doi: 10.1002/jps.2600620302. [DOI] [PubMed] [Google Scholar]
  21. Braverman L. E., Ingbar S. H. Effects of norethandrolone on the transport in serum and peripheral turnover of thyroxine. J Clin Endocrinol Metab. 1967 Mar;27(3):389–396. doi: 10.1210/jcem-27-3-389. [DOI] [PubMed] [Google Scholar]
  22. Burton J. L., Loudon N. B., Wilson A. T. Urinary coproporphyrin excretion and hepatic function in women taking oral contraceptives. Lancet. 1967 Dec 23;2(7530):1326–1327. doi: 10.1016/s0140-6736(67)90912-9. [DOI] [PubMed] [Google Scholar]
  23. Byar D. P. Treatment of prostatic cancer: studies by the Veterans Administration cooperative urological research group. Bull N Y Acad Med. 1972 Jun;48(5):751–766. [PMC free article] [PubMed] [Google Scholar]
  24. Böttiger L. E., Westerholm B. Oral contraceptives and thromboembolic disease. Swedish experience. Acta Med Scand. 1971 Nov;190(5):455–463. doi: 10.1111/j.0954-6820.1971.tb07459.x. [DOI] [PubMed] [Google Scholar]
  25. COMBES B., SHIBATA H., ADAMS R., MITCHELL B. D., TRAMMELL V. ALTERATIONS IN SULFOBROMOPHTHALEIN SODIUM-REMOVAL MECHANISMS FROM BLOOD DURING NORMAL PREGNANCY. J Clin Invest. 1963 Sep;42:1431–1442. doi: 10.1172/JCI104828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Cain M. D., Walters W. A., Catt K. J. Effects of oral contraceptive therapy on the renin-angiotensin system. J Clin Endocrinol Metab. 1971 Oct;33(4):671–676. doi: 10.1210/jcem-33-4-671. [DOI] [PubMed] [Google Scholar]
  27. Carlson L. A., Böttiger L. E. Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study. Lancet. 1972 Apr 22;1(7756):865–868. doi: 10.1016/s0140-6736(72)90738-6. [DOI] [PubMed] [Google Scholar]
  28. Carruthers M. E., Hobbs C. B., Warren R. L. Raised serum copper and caeruloplasmin levels in subjects taking oral contraceptives. J Clin Pathol. 1966 Sep;19(5):498–500. doi: 10.1136/jcp.19.5.498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Carstens H. B., Clemmesen J. Genital-tract cancer in Danish adolescents. N Engl J Med. 1972 Jul 27;287(4):198–198. doi: 10.1056/NEJM197207272870420. [DOI] [PubMed] [Google Scholar]
  30. Clezy T. M., Foy B. N., Hodge R. L., Lumbers E. R. Oral contraceptives and hypertension. An epidemiological survey. Br Heart J. 1972 Dec;34(12):1238–1243. doi: 10.1136/hrt.34.12.1238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Cole P., MacMahon B. Oestrogen fractions during early reproductive life in the aetiology of breast cancer. Lancet. 1969 Mar 22;1(7595):604–606. doi: 10.1016/s0140-6736(69)91537-2. [DOI] [PubMed] [Google Scholar]
  32. Corvol P. L., Chrambach A., Rodbard D., Bardin C. W. Physical properties and binding capacity of testosterone-estradiol-binding globulin in human plasma, determined by polyacrylamide gel electrophoresis. J Biol Chem. 1971 Jun 10;246(11):3435–3443. [PubMed] [Google Scholar]
  33. Coutinho E. M., Mattos C. E., Sant'Anna A. R., Filho J. A., Silva M. C., Tatum H. J. Further studies on long-term contraception by subcutaneous silastic R capsules containing megestrol acetate. Contraception. 1972 May;5(5):389–393. doi: 10.1016/0010-7824(72)90030-3. [DOI] [PubMed] [Google Scholar]
  34. DOWLING J. T., FREINKEL N., INGBAR S. H. Effect of diethylstilbestrol on the binding of thyroxine in serum. J Clin Endocrinol Metab. 1956 Nov;16(11):1491–1506. doi: 10.1210/jcem-16-11-1491. [DOI] [PubMed] [Google Scholar]
  35. Daniel D. G., Campbell H., Turnbull A. C. Puerperal thromboembolism and suppression of lactation. Lancet. 1967 Aug 5;2(7510):287–289. doi: 10.1016/s0140-6736(67)90117-1. [DOI] [PubMed] [Google Scholar]
  36. Davidoff F., Tishler S., Rosoff C. Marked hyperlipidemia and pancreatitis associated with oral contraceptive therapy. N Engl J Med. 1973 Sep 13;289(11):552–555. doi: 10.1056/NEJM197309132891103. [DOI] [PubMed] [Google Scholar]
  37. Davidson M. B., Holzman G. B. Role of growth hormone in the alteration of carbohydrate metabolism induced by oral contraceptive agents. J Clin Endocrinol Metab. 1973 Feb;36(2):246–255. doi: 10.1210/jcem-36-2-246. [DOI] [PubMed] [Google Scholar]
  38. Deshpande N., Jensen V., Bulbrook R. D. Accumulation of tritiated oestradiol by human breast tissue. Steroids. 1967 Sep;10(3):219–232. doi: 10.1016/0039-128x(67)90049-9. [DOI] [PubMed] [Google Scholar]
  39. Dietary and drug treatment of primary hyperlipoproteinemia. Ann Intern Med. 1972 Aug;77(2):267–294. doi: 10.7326/0003-4819-77-2-267. [DOI] [PubMed] [Google Scholar]
  40. Drill V. A., Calhoun D. W. Oral contraceptives and thromboembolic disease. II. Estrogen content of oral contraceptives. JAMA. 1972 Jan 31;219(5):593–596. [PubMed] [Google Scholar]
  41. Drill V. A., Calhoun D. W. Oral contraceptives and thromboembolic disease. JAMA. 1968 Sep 30;206(1):77–84. [PubMed] [Google Scholar]
  42. Drill V. A. Oral contraceptives and thromboembolic disease. I. Prospective and retrospective studies. JAMA. 1972 Jan 31;219(5):583–592. [PubMed] [Google Scholar]
  43. Eaton R. P., Kipnis D. M. Effect of glucose feeding on lipoprotein synthesis in the rat. Am J Physiol. 1969 Oct;217(4):1153–1159. doi: 10.1152/ajplegacy.1969.217.4.1153. [DOI] [PubMed] [Google Scholar]
  44. Emmens C. W. Postcoital contraception. Br Med Bull. 1970 Jan;26(1):45–51. doi: 10.1093/oxfordjournals.bmb.a070742. [DOI] [PubMed] [Google Scholar]
  45. FEDERMAN D. D., ROBBINS J., RALL J. E. Effects of methyl testosterone on thyroid function, thyrozine metabolism, and thyroxine-binding protein. J Clin Invest. 1958 Jul;37(7):1024–1030. doi: 10.1172/JCI103683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. FLORSHEIM W. H., FAIRCLOTH M. A. EFFECTS OF ORAL OVULATION INHIBITORS ON SERUM PROTEIN-BOUND IODINE AND THYROXINE BINDING PROTEINS. Proc Soc Exp Biol Med. 1964 Oct;117:56–58. doi: 10.3181/00379727-117-29495. [DOI] [PubMed] [Google Scholar]
  47. Fechner R. E. Fibroadenomas in patients receiving oral contraceptives: a clinical and pathologic study. Am J Clin Pathol. 1970 Jun;53(6):857–864. doi: 10.1093/ajcp/53.6.857. [DOI] [PubMed] [Google Scholar]
  48. Fechner R. E. Fibrocystic disease in women receiving oral contraceptive hormones. Cancer. 1970 Jun;25(6):1332–1339. doi: 10.1002/1097-0142(197006)25:6<1332::aid-cncr2820250611>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  49. Fisher D. A., Oddie T. H. Effect of methyl testosterone on thyroxine metabolism and on triiodothyronine kinetics. J Clin Endocrinol Metab. 1968 Dec;28(12):1690–1698. doi: 10.1210/jcem-28-12-1690. [DOI] [PubMed] [Google Scholar]
  50. Fisher D. A., Oddie T. H., Epperson D. Norethynodrel-mestranol and thyroid function. J Clin Endocrinol Metab. 1966 Aug;26(8):878–884. doi: 10.1210/jcem-26-8-878. [DOI] [PubMed] [Google Scholar]
  51. Flax H., Salih H., Newton K. A., Hobbs J. R. Are some women's breast cancers androgen dependent? Lancet. 1973 Jun 2;1(7814):1204–1207. doi: 10.1016/s0140-6736(73)90524-2. [DOI] [PubMed] [Google Scholar]
  52. Fraser R. C., Cudmore D. C., Malanson J., Morse W. I. The metabolism and production rate of estradiol-17-beta in premenopausal women with cervical carcinoma. Am J Obstet Gynecol. 1967 Jun 15;98(4):509–515. doi: 10.1016/0002-9378(67)90104-4. [DOI] [PubMed] [Google Scholar]
  53. Fredrickson D. S., Levy R. I., Lees R. S. Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med. 1967 Jan 5;276(1):34–contd. doi: 10.1056/NEJM196701052760107. [DOI] [PubMed] [Google Scholar]
  54. Gallagher T. F., Fukushima D. K., Noguchi S., Fishman J., Bradlow H. L., Cassouto J., Zumoff B., Hellman L. Recent studies in steroid hormone metabolism in man. Recent Prog Horm Res. 1966;22:283–303. doi: 10.1016/b978-1-4831-9825-5.50010-5. [DOI] [PubMed] [Google Scholar]
  55. Gallagher T. F., Jr, Mueller M. N., Kappas A. Studies on the mechanism and structural specificity of the estrogen effect on BSP metabolism. Trans Assoc Am Physicians. 1965;78:187–195. [PubMed] [Google Scholar]
  56. Glueck C. J., Levy R. I., Fredrickson D. S. Norethindrone acetate, postheparin lipolytic activity, and plasma triglycerides in familial types I, 3, IV, and V hyperlipoproteinemia. Studies in 26 patients and 5 normal persons. Ann Intern Med. 1971 Sep;75(3):345–352. doi: 10.7326/0003-4819-75-3-345. [DOI] [PubMed] [Google Scholar]
  57. Glueck C. J., Scheel D., Fishback J., Steiner P. Estrogen-induced pancreatitis in patients with previously covert familial type V hyperlipoproteinemia. Metabolism. 1972 Jul;21(7):657–666. doi: 10.1016/0026-0495(72)90089-3. [DOI] [PubMed] [Google Scholar]
  58. Goldman J. A., Eckerling B. Blood glucose levels and glucose tolerance in women with subclinical diabetes receiving an oral contraceptive. Am J Obstet Gynecol. 1970 May 15;107(2):325–327. doi: 10.1016/0002-9378(70)90608-3. [DOI] [PubMed] [Google Scholar]
  59. Goldman J. A., Eckerling B., Ovadia J. The effect of pseudopregnancy by ovulatory suppressants on the glucose tolerance in women. Fertil Steril. 1969 May-Jun;20(3):393–399. doi: 10.1016/s0015-0282(16)37024-8. [DOI] [PubMed] [Google Scholar]
  60. Goldman J. A., Eckerling B., Zukerman Z., Mannheimer S. Blood glucose and plasma insulin levels with ethynodiol diacetate oral contraceptive. J Obstet Gynaecol Br Commonw. 1971 Mar;78(3):255–260. doi: 10.1111/j.1471-0528.1971.tb00265.x. [DOI] [PubMed] [Google Scholar]
  61. Goldman J. A., Ovadia J. L., Eckerling B. Effect of progesterone on glucose tolerance in women. Isr J Med Sci. 1968 Jul-Aug;4(4):878–882. [PubMed] [Google Scholar]
  62. HELMER O. M., GRIFFITH R. S. The effect of the administration of estrogens on the renin-substrate (hypertensinogen) content of rat plasma. Endocrinology. 1952 Nov;51(5):421–426. doi: 10.1210/endo-51-5-421. [DOI] [PubMed] [Google Scholar]
  63. HSIA D. Y., DOWBEN R. M., RIABOV S. INHIBITORS OF GLUCURONYL TRANSFERASE IN THE NEWBORN. Ann N Y Acad Sci. 1963 Dec 30;111:326–336. doi: 10.1111/j.1749-6632.1963.tb36975.x. [DOI] [PubMed] [Google Scholar]
  64. Hausknecht R. U., Gusberg S. B. Estrogen metabolism in patients at high risk for endometrial carcinoma. I. Urinary metabolites of H3-estradiol in normal postmenopausal women and those with endometrial carcinoma. Am J Obstet Gynecol. 1969 Dec 15;105(8):1161–1167. doi: 10.1016/0002-9378(69)90283-x. [DOI] [PubMed] [Google Scholar]
  65. Hazzard W. R., Notter D. T., Spiger M. J., Bierman E. L. Oral contraceptives and triglyceride transport: acquired heparin resistance as the mechanism for impaired post-heparin lipolytic activity. J Clin Endocrinol Metab. 1972 Sep;35(3):425–437. doi: 10.1210/jcem-35-3-425. [DOI] [PubMed] [Google Scholar]
  66. Hazzard W. R., Spiger M. J., Bagdade J. D., Bierman E. L. Studies on the mechanism of increased plasma triglyceride levels induced by oral contraceptives. N Engl J Med. 1969 Feb 27;280(9):471–474. doi: 10.1056/NEJM196902272800904. [DOI] [PubMed] [Google Scholar]
  67. Herbst A. L., Kurman R. J., Scully R. E., Poskanzer D. C. Clear-cell adenocarcinoma of the genital tract in young females. Registry report. N Engl J Med. 1972 Dec 21;287(25):1259–1264. doi: 10.1056/NEJM197212212872501. [DOI] [PubMed] [Google Scholar]
  68. Herbst A. L., Kurman R. J., Scully R. E., Poskanzer D. C. Clear-cell adenocarcinoma of the genital tract in young females. Registry report. N Engl J Med. 1972 Dec 21;287(25):1259–1264. doi: 10.1056/NEJM197212212872501. [DOI] [PubMed] [Google Scholar]
  69. Herbst A. L., Scully R. E. Adenocarcinoma of the vagina in adolescence. A report of 7 cases including 6 clear-cell carcinomas (so-called mesonephromas). Cancer. 1970 Apr;25(4):745–757. doi: 10.1002/1097-0142(197004)25:4<745::aid-cncr2820250402>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  70. Herbst A. L., Ulfelder H., Poskanzer D. C. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971 Apr 15;284(15):878–881. doi: 10.1056/NEJM197104222841604. [DOI] [PubMed] [Google Scholar]
  71. Inman W. H., Vessey M. P. Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. Br Med J. 1968 Apr 27;2(5599):193–199. doi: 10.1136/bmj.2.5599.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Inman W. H., Vessey M. P., Westerholm B., Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J. 1970 Apr 25;2(5703):203–209. doi: 10.1136/bmj.2.5703.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Jennett W. B., Cross J. N. Influence of pregnancy and oral contraception on the incidence of strokes in women of childbearing age. Lancet. 1967 May 13;1(7498):1019–1023. doi: 10.1016/s0140-6736(67)91539-5. [DOI] [PubMed] [Google Scholar]
  74. Jensen E. V., DeSombre E. R. Mechanism of action of the female sex hormones. Annu Rev Biochem. 1972;41:203–230. doi: 10.1146/annurev.bi.41.070172.001223. [DOI] [PubMed] [Google Scholar]
  75. Jeppsson S., Kullander S. Experience with chlormadinone acetate in continuous low dose as an oral contraceptive. Fertil Steril. 1970 Apr;21(4):307–313. doi: 10.1016/s0015-0282(16)37446-5. [DOI] [PubMed] [Google Scholar]
  76. Jones D. P., Arky R. A. Effects of insulin on triglyceride and free fatty acid metabolism in man. Metabolism. 1965 Dec;14(12):1287–1293. doi: 10.1016/s0026-0495(65)80010-5. [DOI] [PubMed] [Google Scholar]
  77. KLEINER G. J., KRESCH L., ARIAS I. M. STUDIES ON HEPATIC EXCRETARY FUNCTION. II. THE EFFECT OF NORETHYNODREL AND MESTRANOL ON BROMSULFALIEN SODIUM METABOLISM IN WOMEN OF CHILDBEARING AGE. N Engl J Med. 1965 Aug 19;273:420–423. doi: 10.1056/NEJM196508192730804. [DOI] [PubMed] [Google Scholar]
  78. KORY R. C., BRADLEY M. H., WATSON R. N., CALLAHAN R., PETERS B. J. A six-month evaluation of an anabolic drug, norethandrolone, in underweight persons. II. Bromsulphalein (BSP) retention and liver function. Am J Med. 1959 Feb;26(2):243–248. doi: 10.1016/0002-9343(59)90313-4. [DOI] [PubMed] [Google Scholar]
  79. Kekki M., Nikkilä E. A. Plasma triglyceride turnover during use of oral contraceptives. Metabolism. 1971 Sep;20(9):878–889. doi: 10.1016/0026-0495(71)90050-3. [DOI] [PubMed] [Google Scholar]
  80. Kitay J. I., Coyne M. D., Swygert N. H. Influence of gonadectomy and replacement with estradiol or testosterone on formation of 5 alpha-reduced metabolites of corticosterone by the adrenal gland of the rat. Endocrinology. 1970 Dec;87(6):1257–1265. doi: 10.1210/endo-87-6-1257. [DOI] [PubMed] [Google Scholar]
  81. Kuchera L. K. Postcoital contraception with diethylstilbestrol. JAMA. 1971 Oct 25;218(4):562–563. doi: 10.1001/jama.218.4.562. [DOI] [PubMed] [Google Scholar]
  82. Kwiterovich P. O., Jr, Margolis S. Type IV hyperlipoproteinaemia. Clin Endocrinol Metab. 1973 Mar;2(1):41–71. doi: 10.1016/s0300-595x(73)80026-x. [DOI] [PubMed] [Google Scholar]
  83. LARSSON-COHN U. ORAL CONTRACEPTION AND LIVER-FUNCTION TESTS. Br Med J. 1965 May 29;1(5447):1414–1415. doi: 10.1136/bmj.1.5447.1414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Larsson-Cohn U., Berlin R., Vikrot O. Effects of combined and low-dose gestagen oral contraceptives on plasma lipids; including individual phospholipids. Acta Endocrinol (Copenh) 1970 Apr;63(4):717–735. doi: 10.1530/acta.0.0630717. [DOI] [PubMed] [Google Scholar]
  85. Larsson-Cohn U., Stenram U. Liver ultrastructure and function in icteric and non-icteric women using oral contraceptive agents. Acta Med Scand. 1967 Mar;181(3):257–264. doi: 10.1111/j.0954-6820.1967.tb15151.x. [DOI] [PubMed] [Google Scholar]
  86. Laurell C. B., Kullander S., Thorell J. Effect of administration of a combined estrogen-progestin contraceptive on the level of individual plasma proteins. Scand J Clin Lab Invest. 1968;21(4):337–343. doi: 10.3109/00365516809077003. [DOI] [PubMed] [Google Scholar]
  87. Laurell C. B., Kullander S., Thorell J. Rate of plasma protein normalization after parturition and withdrawal of oral contraceptives. Scand J Clin Lab Invest. 1970 Dec;26(4):345–348. doi: 10.3109/00365517009046244. [DOI] [PubMed] [Google Scholar]
  88. Lemon H. M. Abnormal estrogen metabolism and tissue estrogen receptor proteins in breast cancer. Cancer. 1970 Feb;25(2):423–435. doi: 10.1002/1097-0142(197002)25:2<423::aid-cncr2820250222>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  89. Lipsett M. B., Combs J. W., Jr, Catt K., Seigel D. G. Problems in contraception. Ann Intern Med. 1971 Feb;74(2):251–263. doi: 10.7326/0003-4819-74-2-251. [DOI] [PubMed] [Google Scholar]
  90. Lipsett M. B., Combs J. W., Jr, Catt K., Seigel D. G. Problems in contraception. Ann Intern Med. 1971 Feb;74(2):251–263. doi: 10.7326/0003-4819-74-2-251. [DOI] [PubMed] [Google Scholar]
  91. Lipsett M. B., Combs J. W., Jr, Catt K., Seigel D. G. Problems in contraception. Ann Intern Med. 1971 Feb;74(2):251–263. doi: 10.7326/0003-4819-74-2-251. [DOI] [PubMed] [Google Scholar]
  92. MUELLER M. N., KAPPAS A. ESTROGEN PHARMACOLOGY. I. THE INFLUENCE OF ESTRADIOL AND ESTRIOL ON HEPATIC DISPOSAL OF SULFOBROMOPHTHALEIN (BSP) IN MAN. J Clin Invest. 1964 Oct;43:1905–1914. doi: 10.1172/JCI105064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. MacMahon B., Cole P., Brown J. B., Aoki K., Lin T. M., Morgan R. W., Woo N. Oestrogen profiles of Asian and North American women. Lancet. 1971 Oct 23;2(7730):900–902. doi: 10.1016/s0140-6736(71)92504-9. [DOI] [PubMed] [Google Scholar]
  94. MacMahon B., Cole P., Lin T. M., Lowe C. R., Mirra A. P., Ravnihar B., Salber E. J., Valaoras V. G., Yuasa S. Age at first birth and breast cancer risk. Bull World Health Organ. 1970;43(2):209–221. [PMC free article] [PubMed] [Google Scholar]
  95. Masi A. T., Dugdale M. Cerebrovascular diseases associated with the use of oral contraceptives. A review of the English-language literature. Ann Intern Med. 1970 Jan;72(1):111–121. doi: 10.7326/0003-4819-72-1-111. [DOI] [PubMed] [Google Scholar]
  96. McQueen E. G. Hormonal steroid contraceptives. IV. Adverse reactions and management of the patient. Drugs. 1971;2(2):138–164. doi: 10.2165/00003495-197102020-00003. [DOI] [PubMed] [Google Scholar]
  97. Melamed M. R., Koss L. G., Flehinger B. J., Kelisky R. P., Dubrow H. Prevalence rates of uterine cervical carcinoma in situ for women using the diaphragm or contraceptive oral steroids. Br Med J. 1969 Jul 26;3(5664):195–200. doi: 10.1136/bmj.3.5664.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Miller W. R., McDonald D., Forrest A. P., Shivas A. A. Metabolism of androgens by human breast tissue. Lancet. 1973 Apr 28;1(7809):912–913. doi: 10.1016/s0140-6736(73)91363-9. [DOI] [PubMed] [Google Scholar]
  99. Mishell D. R., Jr, Kharma K. M., Thorneycroft I. H., Nakamura R. M. Estrogenic activity in women receiving an injectable progestogen for contraception. Am J Obstet Gynecol. 1972 Jun 1;113(3):372–376. doi: 10.1016/0002-9378(72)90687-4. [DOI] [PubMed] [Google Scholar]
  100. Mishell D. R., Jr, Odell W. D. Effect of varying dosages of ethynodiol diacetate upon serum luteinizing hormone. Am J Obstet Gynecol. 1971 Jan 1;109(1):140–149. doi: 10.1016/0002-9378(71)90849-0. [DOI] [PubMed] [Google Scholar]
  101. Nestel P. J., Carroll K. F., Havenstein N. Plasma triglyceride response to carbohydrates, fats and caloric intake. Metabolism. 1970 Jan;19(1):1–18. doi: 10.1016/0026-0495(70)90112-5. [DOI] [PubMed] [Google Scholar]
  102. Nygren K. G., Johansson E. D., Wide L. Postovulatory contraception in women with large doses of norethindrone. Contraception. 1972 Jun;5(6):445–456. doi: 10.1016/0010-7824(72)90011-x. [DOI] [PubMed] [Google Scholar]
  103. O'Donnell J. M., McAleer R. Tinea nigra palmaris. Med J Aust. 1968 Aug 10;2(6):268–270. doi: 10.5694/j.1326-5377.1968.tb29420.x. [DOI] [PubMed] [Google Scholar]
  104. Ockner R. K., Davidson C. S. Hepatic effects of oral contraceptives. N Engl J Med. 1967 Feb 9;276(6):331–334. doi: 10.1056/NEJM196702092760607. [DOI] [PubMed] [Google Scholar]
  105. Oliver M. F. Oral contraceptives and myocardial infarction. Br Med J. 1970 Apr 25;2(5703):210–213. doi: 10.1136/bmj.2.5703.210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Osman M. M., Toppozada H. K., Ghanem M. H., Guergis F. K. The effect of an oral contraceptive on serum lipids. Contraception. 1972 Feb;5(2):105–118. doi: 10.1016/0010-7824(72)90022-4. [DOI] [PubMed] [Google Scholar]
  107. Owen G. Hypertension associated with oral contraceptives. Can Med Assoc J. 1966 Jul 23;95(4):167–167. [PMC free article] [PubMed] [Google Scholar]
  108. Phillips N., Duffy T. One-hour glucose tolerance in relation to the use of contraceptive drugs. Am J Obstet Gynecol. 1973 May 1;116(1):91–100. doi: 10.1016/0002-9378(73)90890-9. [DOI] [PubMed] [Google Scholar]
  109. RAYMUNT J., RUSS E. M. Influence of estrogens on total serum copper and caeruloplasmin. Proc Soc Exp Biol Med. 1956 Jul;92(3):465–466. doi: 10.3181/00379727-92-22512. [DOI] [PubMed] [Google Scholar]
  110. ROBBINS J., RALL J. E. The interaction of thyroid hormones and protein in biological fluids. Recent Prog Horm Res. 1957;13:161–208. [PubMed] [Google Scholar]
  111. Reaven G. M., Lerner R. L., Stern M. P., Farquhar J. W. Role of insulin in endogenous hypertriglyceridemia. J Clin Invest. 1967 Nov;46(11):1756–1767. doi: 10.1172/JCI105666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Roland M. Prevention of sperm migration into the uterine cavity by a microdose progestagen. Fertil Steril. 1970 Mar;21(3):211–216. doi: 10.1016/s0015-0282(16)37383-6. [DOI] [PubMed] [Google Scholar]
  113. Rössner S., Larsson-Cohn U., Carlson L. A., Boberg J. Effects of an oral contraceptive agent on plasma lipids, plasma lipoproteins, the intravenous fat tolerance and the post-heparin lipoprotein lipase activity. Acta Med Scand. 1971 Oct;190(4):301–305. doi: 10.1111/j.0954-6820.1971.tb07435.x. [DOI] [PubMed] [Google Scholar]
  114. SANDBERG E. C., DANIELSON R. W., CAUWET R. W., BONAR B. E. ADENOSIS VAGINAE. Am J Obstet Gynecol. 1965 Sep 15;93:209–222. doi: 10.1016/0002-9378(65)90660-5. [DOI] [PubMed] [Google Scholar]
  115. STAMLER J., PICK R., KATZ L. N., PICK A., KAPLAN B. M., BERKSON D. M., CENTURY D. Effectiveness of estrogens for therapy of myocardial infarction in middle-age men. JAMA. 1963 Feb 23;183:632–638. doi: 10.1001/jama.1963.03700080040013. [DOI] [PubMed] [Google Scholar]
  116. Sachs B. A., Wolfman L., Herzig N. Plasma lipid and lipoprotein alterations during oral contraceptive administration. Obstet Gynecol. 1969 Oct;34(4):530–535. [PubMed] [Google Scholar]
  117. Sartwell P. E., Arthes F. G., Tonascia J. A. Epidemiology of benign breast lesions: lack of association with oral contraceptive use. N Engl J Med. 1973 Mar 15;288(11):551–554. doi: 10.1056/NEJM197303152881104. [DOI] [PubMed] [Google Scholar]
  118. Sartwell P. E., Masi A. T., Arthes F. G., Greene G. R., Smith H. E. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol. 1969 Nov;90(5):365–380. doi: 10.1093/oxfordjournals.aje.a121082. [DOI] [PubMed] [Google Scholar]
  119. Saruta T., Saade G. A., Kaplan N. M. A possible mechanism for hypertension induced by oral contraceptives. Diminished feedback suppression of renin release. Arch Intern Med. 1970 Oct;126(4):621–626. [PubMed] [Google Scholar]
  120. Schally A. V., Parlow A. F., Carter W. H., Saito M., Bowers C. Y., Arimura A. Studies on the site of action of oral contraceptive steroids. II. Plasma LH and FSH levels after administration of antifertility steroids and LH-releasing hormone(LH-RH). Endocrinology. 1970 Mar;86(3):530–541. doi: 10.1210/endo-86-3-530. [DOI] [PubMed] [Google Scholar]
  121. Schenker J. G., Hellerstein S., Jungreis E., Polishuk W. Z. Serum copper and zinc levels in patients taking oral contraceptives. Fertil Steril. 1971 Apr;22(4):229–234. doi: 10.1016/s0015-0282(16)38162-6. [DOI] [PubMed] [Google Scholar]
  122. Schonfeld G. Changes in the composition of very low density lipoprotein during carbohydrate induction in man. J Lab Clin Med. 1970 Feb;75(2):206–211. [PubMed] [Google Scholar]
  123. Schriefers H. Factors regulating the metabolism of steroids. Vitam Horm. 1967;25:271–314. doi: 10.1016/s0083-6729(08)60038-2. [DOI] [PubMed] [Google Scholar]
  124. Scommegna A., Lee A. W., Borushek S. Evaluation of an injectable progestin-estrogen as a contraceptive. Am J Obstet Gynecol. 1970 Aug 15;107(8):1147–1155. doi: 10.1016/s0002-9378(15)30363-x. [DOI] [PubMed] [Google Scholar]
  125. Sherman A. I. Progesterone caproate in the treatment of endometrial cancer. Obstet Gynecol. 1966 Sep;28(3):309–314. [PubMed] [Google Scholar]
  126. Song C. S., Kappas A. The influence estrogens, progestins, and pregnancy on the liver. Vitam Horm. 1968;26:147–195. doi: 10.1016/s0083-6729(08)60754-2. [DOI] [PubMed] [Google Scholar]
  127. Song C. S., Merkatz I. R., Rifkind A. B., Gillette P. N., Kappas A. The influence of pregnancy and oral contraceptive steroids on the concentration of plasma proteins. Studies with a quantitative immunodiffusion method. Am J Obstet Gynecol. 1970 Sep 15;108(2):227–231. doi: 10.1016/0002-9378(70)90301-7. [DOI] [PubMed] [Google Scholar]
  128. Spellacy W. N. A review of carbohydrate metabolism and the oral contraceptives. Am J Obstet Gynecol. 1969 Jun 1;104(3):448–460. doi: 10.1016/s0002-9378(16)34204-1. [DOI] [PubMed] [Google Scholar]
  129. Spellacy W. N., Birk S. A. The effect of intrauterine devices, oral contraceptives, estrogens, and progestogens on blood pressure. Am J Obstet Gynecol. 1972 Apr 1;112(7):912–919. doi: 10.1016/0002-9378(72)90811-3. [DOI] [PubMed] [Google Scholar]
  130. Spellacy W. N., Buhi W. C., Bendel R. P. Growth hormone alterations by a sequential-type oral contraceptive. Obstet Gynecol. 1969 Apr;33(4):506–510. [PubMed] [Google Scholar]
  131. Spellacy W. N., Buhi W. C., Bendel R. P. Growth hormone and glucose levels after one year of combination-type oral contraceptive treatment. Int J Fertil. 1969 Jan-Mar;14(1):51–55. [PubMed] [Google Scholar]
  132. Spellacy W. N., Buhi W. C., Birk S. A., McCreary S. A. Studies of chlormadinone acetate and mestranol on blood glucose and plasma insulin. I. Six-month oral glucose tolerance test. Fertil Steril. 1971 Apr;22(4):217–223. [PubMed] [Google Scholar]
  133. Spellacy W. N., Buhi W. C., Birk S. A., McCreary S. A. Studies of chlormadinone acetate and mestranol on blood glucose and plasma insulin. II. Twelfth month oral glucose tolerance test. Fertil Steril. 1971 Apr;22(4):224–228. [PubMed] [Google Scholar]
  134. Spellacy W. N., Buhi W. C., Birk S. A. The effect of estrogens on carbohydrate metabolism: glucose, insulin, and growth hormone studies on one hundred and seventy-one women ingesting Premarin, mestranol, and ethinyl estradiol for six months. Am J Obstet Gynecol. 1972 Oct 1;114(3):378–392. doi: 10.1016/0002-9378(72)90615-1. [DOI] [PubMed] [Google Scholar]
  135. Spellacy W. N., Buhi W. C., Birk S. A. The effect of the progestogen ethynodiol diacetate on glucose, insulin, and growth hormone after six months treatment. Acta Endocrinol (Copenh) 1972 Jun;70(2):373–384. doi: 10.1530/acta.0.0700373. [DOI] [PubMed] [Google Scholar]
  136. Spellacy W. N., Carlson K. L., Schade S. L. Human growth hormone levels in normal subjects receiving an oral contraceptive. JAMA. 1967 Nov 6;202(6):451–454. [PubMed] [Google Scholar]
  137. Starup J., Date J., Deckert T. Serum insulin and intravenous glucose tolerance in oral contraception. Acta Endocrinol (Copenh) 1968 Jul;58(3):537–544. doi: 10.1530/acta.0.0580537. [DOI] [PubMed] [Google Scholar]
  138. Stokes T., Wynn V. Serum-lipids in women on oral contraceptives. Lancet. 1971 Sep 25;2(7726):677–680. doi: 10.1016/s0140-6736(71)92247-1. [DOI] [PubMed] [Google Scholar]
  139. Swerdloff R. S., Odell W. D. Serum luteinizing and follicle stimulating hormone levels during sequential and nonsequential contraceptive treatment of eugonadal women. J Clin Endocrinol Metab. 1969 Feb;29(2):157–163. doi: 10.1210/jcem-29-2-157. [DOI] [PubMed] [Google Scholar]
  140. Szabo A. J., Cole H. S., Grimaldi R. D. Glucose tolerance in gestational diabetic women during and after treatment with a combination-type oral contraceptive. N Engl J Med. 1970 Mar 19;282(12):646–650. doi: 10.1056/NEJM197003192821203. [DOI] [PubMed] [Google Scholar]
  141. TYLER E. T. CURRENT STATUS OF LOS ANGELES ORAL CONTRACEPTION STUDIES. Appl Ther. 1964 Jun;6:507–511. [PubMed] [Google Scholar]
  142. Taymor M. L., Levesque L. A. Levels of serum follicle-stimulating hormone, luteinizing hormone, and plasma progestin during microdose chlormadinone treatment. Fertil Steril. 1971 Jan;22(1):1–8. doi: 10.1016/s0015-0282(16)37980-8. [DOI] [PubMed] [Google Scholar]
  143. Tyson J. E. Oral contraception and elevated blood pressure. Am J Obstet Gynecol. 1968 Mar 15;100(6):875–877. doi: 10.1016/s0002-9378(15)33594-8. [DOI] [PubMed] [Google Scholar]
  144. VALLEE B. L., WACKER W. E., BARTHOLOMAY A. F., HOCH F. L. Zinc metabolism in hepatic dysfunction. II. Correlation of metabolic patterns with biochemical findings. N Engl J Med. 1957 Nov 28;257(22):1055–1065. doi: 10.1056/NEJM195711282572201. [DOI] [PubMed] [Google Scholar]
  145. Vermeulen A., Daneels R., Thiery M. Effects of oral contraceptives on carbohydrate metabolism. Diabetologia. 1970 Oct;6(5):519–523. doi: 10.1007/BF01211894. [DOI] [PubMed] [Google Scholar]
  146. Vessey M. P., Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. Br Med J. 1969 Jun 14;2(5658):651–657. doi: 10.1136/bmj.2.5658.651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  147. Vessey M. P., Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. Br Med J. 1968 Apr 27;2(5599):199–205. doi: 10.1136/bmj.2.5599.199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  148. Vessey M. P., Doll R., Sutton P. M. Oral contraceptives and breast neoplasia: a retrospective study. Br Med J. 1972 Sep 23;3(5829):719–724. doi: 10.1136/bmj.3.5829.719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  149. Walsh F. B., Clark D. B., Thompson R. S., Nicholson D. H. Oral contraceptives and neuro-ophthalmologic interest. Arch Ophthalmol. 1965 Nov;74(5):628–640. doi: 10.1001/archopht.1965.00970040630009. [DOI] [PubMed] [Google Scholar]
  150. Wynn J. W., Doar J. W., Mills G. L. Some effects of oral contraceptives on serum-lipid and lipoprotein levels. Lancet. 1966 Oct 1;2(7466):720–723. doi: 10.1016/s0140-6736(66)92979-5. [DOI] [PubMed] [Google Scholar]
  151. Wynn V., Doar J. W. Some effects of oral contraceptives on carbohydrate metabolism. Lancet. 1966 Oct 1;2(7466):715–719. doi: 10.1016/s0140-6736(66)92978-3. [DOI] [PubMed] [Google Scholar]
  152. Yen S. S., Vela P. Effects of contraceptive steroids on carbohydrate metabolism. J Clin Endocrinol Metab. 1968 Nov;28(11):1564–1570. doi: 10.1210/jcem-28-11-1564. [DOI] [PubMed] [Google Scholar]
  153. Zorrilla E., Hulse M., Hernandez A., Gershberg H. Severe endogenous hypertriglyceridemia during treatment with estrogen and oral contraceptives. J Clin Endocrinol Metab. 1968 Dec;28(12):1793–1796. doi: 10.1210/jcem-28-12-1793. [DOI] [PubMed] [Google Scholar]
  154. de Waard F., Thyssen J. H., Veeman W., Sander P. C. Steroid hormone excretion pattern in women with endometrial carcinoma. Cancer. 1968 Nov;22(5):988–993. doi: 10.1002/1097-0142(196811)22:5<988::aid-cncr2820220513>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES